Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Price Increases Today

The stock of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a huge mover today! The stock increased 4.54% or $2.04 during the last trading session, reaching $47.02. About 546,280 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has risen 29.17% since September 13, 2018 and is uptrending. It has outperformed by 29.17% the S&P500.
The move comes after 8 months positive chart setup for the $2.43B company. It was reported on Sep, 13 by Barchart.com. We have $50.31 PT which if reached, will make NYSE:BHVN worth $170.24 million more.

Analysts await Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report earnings on November, 13. They expect $-2.03 EPS, down 32.68 % or $0.50 from last year’s $-1.53 per share. After $-2.35 actual EPS reported by Biohaven Pharmaceutical Holding Company Ltd. for the previous quarter, Wall Street now forecasts -13.62 % EPS growth.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Coverage

Among 6 analysts covering Biohaven Pharmaceutical (NYSE:BHVN), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Biohaven Pharmaceutical has $10000 highest and $5100 lowest target. $78.17’s average target is 66.25% above currents $47.02 stock price. Biohaven Pharmaceutical had 9 analyst reports since April 9, 2019 according to SRatingsIntel. Oppenheimer maintained the stock with “Outperform” rating in Monday, April 15 report. The firm earned “Equal-Weight” rating on Monday, July 22 by Morgan Stanley. PiperJaffray maintained the stock with “Overweight” rating in Wednesday, May 8 report. Morgan Stanley maintained the shares of BHVN in report on Tuesday, May 14 with “Equal-Weight” rating. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, April 23. The rating was maintained by Canaccord Genuity on Monday, April 15 with “Buy”.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Prnewswire.com which released: “Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial – PRNewswire” on August 07, 2019, also Finance.Yahoo.com with their article: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Bought $201,100 of Shares – Yahoo Finance” published on June 26, 2019, Finance.Yahoo.com published: “Should Biohaven Pharmaceutical Holding (NYSE:BHVN) Be Disappointed With Their 36% Profit? – Yahoo Finance” on June 18, 2019. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Seekingalpha.com and their article: “Biohaven Pharmaceutical: An Intriguing CNS Play – Seeking Alpha” published on August 23, 2019 as well as Seekingalpha.com‘s news article titled: “Biohaven nearing the finish line with migraine med Zydis – Seeking Alpha” with publication date: March 13, 2019.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $2.43 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.